HOME >> BIOLOGY >> NEWS
Cutting The Time And Cost Of Developing New Cures: Lord Sainsbury Launches World's First Biomedical Accelerator Mass Spectrometer In York

The first Accelerator Mass Spectrometer (AMS) in the world to be dedicated to biomedical research is launched officially today (23 November) by Lord Sainsbury, the Minister for Science at CBAMS Ltd.

Identifying promising drugs that could lead to life saving cures in the future can take eight to ten years and cost as much as 200 million. The AMS can investigate large numbers of drugs for pharmaceutical companies, significantly speeding up drug development by quickly identifying the most promising. In some cases it may cut development time by up to six months. With new drugs earning 1 million per day the appeal of using the AMS is obvious. The technique, which is based on carbon dating used to measure the age of ancient finds, will be between one hundred thousand and one million times more sensitive than traditional methods.

"For the first time, pharmaceutical and other biomedical research companies all over the world can access a technique which will speed up drug investigations significantly," said Professor Colin Garner, chief executive officer of CBAMS Ltd. "The technique will also make such investigations safer."

Lord Sainsbury said: "This initiative is a landmark for UK science and reinforces York's position as an important centre for scientific expertise, with a reputation for excellence, initiative and endeavour that is admired internationally."

The AMS is located at the Central Science Laboratory at Sand Hutton, York, and is operated by CBAMS Ltd (the Centre for Biomedical Accelerator Mass Spectrometry), a subsidiary company of the University of York. The machine was purchased with guaranteed contracts for research projects from Glaxo Wellcome, Pfizer, Novartis and Janssen Pharmaceutica.

"CBAMS is a prime example of the sort of start-up company which will be encouraged under the Science City York project," commented Professor Ron Cooke, Vice-Chancellor of the University of York. "CBAMS has worked closely with potential customers
'"/>

Contact: Professor Colin Garner
colin.garner@cbams.co.uk
44-1904-462700
University of York
20-Nov-1998


Page: 1 2

Related biology news :

1. Cutting-edge cancer researchers sought for international recognition
2. Cutting back on cigarettes: when less is more
3. AChemS: Cutting edge research in taste, smell, & chemical irritation
4. Cutting edge
5. Cutting-edge research to be presented at ASCPT pharmacology conference
6. Cutting the risk of coronary disease - start before birth says UK doctor
7. Story Tips: Engineering Students Pursue Cutting-Edge Research
8. Brain Building May Depend On DNA Cutting And Pasting
9. Flexibility In Cutting Toxic Releases Yields Dividends
10. Gene Shears In Cutting Edge Anti-Aids Trial
11. Developing tools for reliable gene chip measurements

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/16/2019)... , ... June 14, 2019 , ... ... invited to lecture at the fifth annual Neodent World Congress. Attended by thousands ... innovative progress and latest advancements in the world of dentistry. The three-day event ...
(Date:6/11/2019)... , ... June 12, 2019 , ... ... antibody discovery services, Abveris plans to leverage the Geneious Biologics platform as a ... Souders, Chief Technology Officer at Abveris, says: “The Geneious team has done an ...
(Date:6/4/2019)... ... June 04, 2019 , ... In’Tech Medical SAS ( ... Q1-19 revenues of $31M, up 12% from Q1-18. The growth is associated with ... & operational excellence initiatives worldwide. , Laurent Pruvost , President & CEO ...
Breaking Biology News(10 mins):
(Date:6/11/2019)... ... June 11, 2019 , ... ... Stem Cells Inc. (PSC) , has announced that their GMP facility for cell ... Drug Branch for manufacturing. This is an important milestone for VetStem as ...
(Date:5/31/2019)... ... May 29, 2019 , ... ... applications from the USPTO providing proprietary interest to our methodology, processes, and ... DISORDER DIAGNOSIS AND TREATMENT… extends Somnology’s IP rights including our proprietary sleep ...
(Date:5/22/2019)... ... May 22, 2019 , ... Artemis (formerly Agrilyst), the ... Series A funding round co-led by Astanor Ventures and Talis Capital ... and iSelect Fund . The company has raised $11.75m to date and ...
(Date:5/14/2019)... ... May 13, 2019 , ... Leak Detection Associates ... the Pharmaceutical, Biotechnology, Medical Device and Food Packaging Industries’ is excited to announce ... to improve LDA’s ability to communicate directly with the marketplace; serving as a ...
Breaking Biology Technology:
Cached News: